Acquisition - August 6, 2013
Affibody signs deal with Daiichi Sankyo
Stockholm-based Affibody AB announces a new collaboration with Japanese Daiichi Sankyo. The license agreement regards the use of Affibody’s proprietary Albumod platform, a platform designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life. The technology will be applied on one undisclosed molecule from Tokyo-based Daiichi Sankyo’s pipeline of proprietary protein therapeutics. Affibody […]
Acquisition - June 11, 2013
AstraZeneca buys Pearl Therapeutics for $1.15 billion
On June 10, AstraZeneca announced the acquisition of California-based Pearl Therapeutics to strengthen the company’s respiratory portfolio. Pearl Therapeutics is a privately held company focused on the development of inhaled small-molecule therapeutics for respiratory disease. The acquisition will according to the press release give AstraZeneca access to a potential new treatment for chronic obstructive pulmonary […]
Acquisition - June 7, 2013
Enzymatica signs agreement with Actavis
Enzymatica and the international pharmaceuticals company, Actavis, have signed a letter of intent on the sale of Enzymatica’s cold treatment product, ColdZyme Mouth Spray, on the Nordic market. Under the agreement, the product will be on sale in around 3,200 pharmacies and a large number of stores, including health food retailers, in the Nordic region. Actavis […]
Acquisition - June 7, 2013
Allenex sells Anamar
Investment company Allenex has agreed to sell its holding in Anamar AB to the company’s main owner Koncentra Holding. Allenex became an owner in AnaMar 1998, whose focus area is chronic joint diseases. However, Allenex has not participated in the financing of AnaMar in recent years and the equity that now is being sold equal about 2,1 […]
Acquisition - May 29, 2013
AstraZeneca acquires Omthera Pharmaceuticals
AstraZeneca has entered into a definitive agreement to acquire Omthera Pharmaeuticals for up to $443m. The specialty pharmaceutical company is based in Princeton, New Jersey, and focuses on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia. The company’s investigational product, EpanovaTM, is aimed at […]
Acquisition - May 24, 2013
Novo A/S acquires Xellia Pharmaceuticals
Novo A/S, the holding company of the Novo Group, has purchased all shares in pharmaceutical group Xellia Pharmaceuticals for approximately USD 700 million. Xellia will now revert to Danish ownership with headquarters in Copenhagen, Denmark following the recent acquisition. Xellia Pharmaceuticals focuses on development, manufacturing and global commercialization of anti-infective therapies. Since its spin-out from Alpharma […]
